Stock 867 CHINA MEDICAL SYSTEM HOLDINGS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Ratings China Medical System Holdings Limited

Equities

867

KYG211081248

Market Closed - Hong Kong S.E.
Other stock markets
 04:09:09 2024-04-25 am EDT 		5-day change 1st Jan Change
7.07 HKD +0.57% Intraday chart for China Medical System Holdings Limited +0.14% -48.92%
Apr. 23 China Medical System's Anti-Anaemia NDA Accepted in China MT
Apr. 23 China Medical System Holdings Limited Announces New Drug Application of Desidustat Tablets Accepted in China CI

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Its low valuation, with P/E ratio at 9.89 and 7.04 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
  • The company's share price in relation to its net book value makes it look relatively cheap.
  • Given the positive cash flows generated by its business, the company's valuation level is an asset.
  • This company will be of major interest to investors in search of a high dividend stock.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

  • The company's earnings growth outlook lacks momentum and is a weakness.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
CHINA MEDICAL SYSTEM HOLDINGS LIMITED Stock China Medical System Holdings Limited
-48.92% 2.19B
B+
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.61% 660B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+24.05% 562B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-5.24% 358B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+16.49% 322B
B-
ABBVIE INC. Stock AbbVie Inc.
+8.28% 297B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+12.74% 219B
B+
ROCHE HOLDING AG Stock Roche Holding AG
-9.73% 196B
A+
NOVARTIS AG Stock Novartis AG
+6.75% 199B
B-
PFIZER, INC. Stock Pfizer, Inc.
-8.75% 149B
C+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 867 Stock
  4. Ratings China Medical System Holdings Limited